So this recent pullback, shaved a tremendous amount off the market cap of SNTA, but the fundamentals of Ganetespib remain unchanged. Given the closet competitor is Crizotinib, I wonder if SNTA is now at risk of being purchased by PFE?
Why? with the Market Cap being cut in half, despite being in phase 3 trials, it sure seems like high probability. Heck, Infinity has a much higher market cap, but isn't into phase 3 like Synta. At this level I think this is definitely a buyout target which is why I think the price moves much higher.